Recombinant Human PLA2G7/Lp-PLA2 Protein (His Tag) (Active)

Cat. No : CDRP-00480

size:

Target Information
Target Name	PLA2G7/Lp-PLA2
Synonyms	2-acetyl-1-alkylglycerophosphocholine esterase; EC 3.1.1; EC 3.1.1.47; 1-alkyl-2-acetylglycerophosphocholine esterase; Group-VIIA phospholipase A2; gVIIA-PLA2; LDL-associated phospholipase A2; LDL-PLA(2); LDL-PLA2; lipoprotein-associated phospholipase A2; LpPLA2; Lp-PLA2; PAF acetylhydrolase; PAF-AH; PAFAHPAF 2-acylhydrolase; phospholipase A2; group VII (platelet-activating factor acetylhydrolase; PLA2G7; plasma); platelet-activating factor acetylhydrolase
UniProt ID	P14921
Accession	Q13093-1

Product Details
Expression Host	HEK293 Cells
Species	Human
Tag	C-His
Molar Mass	49.2 kDa
Sequence	Met 1-Ala 1474

Background
Platelet-activating factor acetylhydrolase; also known as 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycero-phosphocholine esterase; Group-VIIA phospholipase A2; LDL-associated phospholipase A2; PAF 2-acylhydrolase; PLA2G7 and PAFAH; is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7/PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7/PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes; including cardiovascular disease. PLA2G7 also represents an important; potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

Background

Platelet-activating factor acetylhydrolase; also known as 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycero-phosphocholine esterase; Group-VIIA phospholipase A2; LDL-associated phospholipase A2; PAF 2-acylhydrolase; PLA2G7 and PAFAH; is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7/PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7/PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes; including cardiovascular disease. PLA2G7 also represents an important; potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

Properties
Purity	>95% as determined by reducing SDS-PAGE.
Formulation	Lyophilized from sterile 50 mM NaAc, 150 mM NaCl, 10% Glycerol, pH5.0.
Reconstitution	Please refer to the printed manual for detailed information.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8 °C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 °C for 3 months.

! For research use only. Not intended for any clinical use.